Article Information
vol. 27 no. 150
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 15, 2018
- Accepted November 23, 2018
- Published online December 21, 2018.
Copyright & Usage
Copyright ©ERS 2018. ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Colin Holtze1,7⇑,
- Kevin Flaherty1,
- Michael Kreuter2,
- Fabrizio Luppi3,
- Teng Moua4,
- Carlo Vancheri5 and
- Mary B. Scholand6,7
- 1Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
- 2Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, member of the German Center for Lung Research, Heidelberg, Germany
- 3Centre for Rare Lung Disease, University Hospital, Modena, Italy
- 4Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
- 5Dept of Clinical and Experimental Medicine, University of Catania, University Hospital “Policlinico - Vitt. Emanuele”, Catania, Italy
- 6Dept of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- 7Both authors contributed equally
- Colin Holtze, Division of Pulmonary and Critical Care Medicine, University of Michigan, North Campus Research Complex, Building 014-G012, 2800 Plymouth Road, SPC 5642, Ann Arbor, MI 48109-5642, USA. E-mail: choltze{at}med.umich.edu
Article usage
Altmetrics
Vol 27 Issue 150
Table of Contents
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Understanding the burden and assessing healthcare utilisation and costs of ILDs that may present a progressive fibrosing phenotype
- Domains of healthcare utilisation of ILDs that may present a progressive fibrosing phenotype: gaps and unmet needs
- Conclusions
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics